The Use of PARP Inhibitors in Cancer Therapy: Use as Adjuvant with Chemotherapy or Radiotherapy, Use as a Single Agent in Susceptible Patients, and Techniques Used to Identify Susceptible Patients

    Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

    6 Citations (Scopus)

    Abstract

    This chapter describes some of the techniques in use in our laboratories for the investigation of PARP inhibitors in clinical medicine. More specifically, we are involved in investigating the utility of PARP inhibitors in the treatment of hematopoietic malignancies. We are also actively investigating the properties of the PARP systems in cell biology. We begin the chapter with a very brief history of the invention and use of PARP inhibitors. We then explain the underlying logic of the use of PARP inhibitors either in combination with chemo- or radiotherapy or as single agents used alone. We then provide in full detail the protocols that we use to study PARP inhibitors in cell biology to identify patients that should be susceptible to PARP inhibitor treatment and to manage and investigate these patients throughout their treatment.

    Original languageEnglish
    Title of host publicationPoly(ADP-Ribose) Polymerase
    Subtitle of host publicationMethods and Protocols
    PublisherSpringer
    Pages343-370
    Number of pages28
    Volume1608
    ISBN (Print)978-1-4939-6993-7
    DOIs
    Publication statusE-pub ahead of print - 11 Jul 2017

    Publication series

    NameMethods in Molecular Biology (MIMB)
    Volume1608

    Keywords

    • Journal Article

    Fingerprint

    Dive into the research topics of 'The Use of PARP Inhibitors in Cancer Therapy: Use as Adjuvant with Chemotherapy or Radiotherapy, Use as a Single Agent in Susceptible Patients, and Techniques Used to Identify Susceptible Patients'. Together they form a unique fingerprint.

    Cite this